期刊文献+

哌拉西林/他唑巴坦治疗老年医院获得性肺炎不同给药方式对药动学/药效学的影响 被引量:4

下载PDF
导出
摘要 目的探讨哌拉西林/他唑巴坦治疗老年医院获得性肺炎(HAP)不同给药方式对药动学(PK)/药效学(PD)的影响。方法将30例HAP对哌拉西林/他唑巴坦敏感患者随机分为30min静脉滴注组及3h静脉滴注组各15例。30min静脉滴注组静脉注射哌拉西林/他唑巴坦4.5g,每8h 1次,于30min滴完。3h静脉滴注组静脉注射哌拉西林/他唑巴坦4.5g,每8h 1次,于3h滴完。2组均分别于滴注开始的0min、30min、1h、1.5h、2h、2.5h、3h、3.5h、4h、5h、6h、8h采静脉血。采用反相高效液相色普法(HPLC)测定血液浓度。结果 30min静脉滴注组哌拉西林的Cmax及AUC0-8明显高于3h静脉滴注组,差异有统计学意义(P<0.05)。2种哌拉西林用药方式的半衰期t1/2差异无统计学意义(P>0.05)。30min静脉滴注组他唑巴坦Cmax低于3h静脉滴注组Cmax,差异有统计学意义(P<0.05)。2组AUC0-8及半衰期t1/2比较差异无统计学意义(P>0.05)。结论哌拉西林/他唑巴坦输注方案从PK/PD提示持续静脉滴注用药较快速静脉滴注组可提高临床疗效。
出处 《临床合理用药杂志》 2014年第25期105-106,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献5

二级参考文献17

  • 1于燕.1例机械通气气管切口处大肠埃希菌感染的护理[J].中国实用护理杂志(下旬版),2004,20(10):65-65. 被引量:2
  • 2王国权,范静,万红.重症监护病房医院感染与控制感染措施[J].中华医院感染学杂志,2006,16(8):912-913. 被引量:48
  • 3张润香,冯伟,熊建球.临床医护人员洗手现状与方法探讨[J].中华医院感染学杂志,2006,16(10):1138-1139. 被引量:102
  • 4苏红熙主编.重症加强监护学.第1版.北京:人民卫生出版社,1996.345.
  • 5张帮燮主编.医院感染.第1版,四川:四川科学技术出版社,1985.69.
  • 6Jason AR, Jennifer P, Elizabeth P, et al. Continuous infusion of β-lactam antibiotics in severe infections : a review of its role [J]. Int J Antimicrob Agents,2007,30(1) :11-18.
  • 7Shea KM, Cheatham SC, Wack MF,et al. Steady-state pharma- cokinetics and pharmacodynamics of piperacillin/tazobactam ad- ministered by prolonged infusion in hospitalised patients[J]. Int J Antimicrob Agents, 2009,34 (5) : 429-433.
  • 8Lodise TP, Lomaestro B, Drusano GL. Peperacillin-tazobac- tam for pseudomonas aeruginosa infection: clinical implica- tions of an extended-infusion dosing strategy[J]. Clin Infect Dis, 2007,44 (3) : 357-363.
  • 9王丽,马杰,李顺清,肖娟.重症监护病房革兰阴性杆菌耐药性监测[J].中华医院感染学杂志,2007,17(9):1145-1146. 被引量:17
  • 10Gutierrez O,Juan C,Cercenado E,etal. Molecular epidemiolo- gy and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals[J]. Antimicrob A- gents Chemother, 2007,51 (12) 4329-4335.

共引文献29

同被引文献48

  • 1Zuppa AF, Nieolson SC, Barrett JS, et al. Population pharmacoki- netics ofpentobarbital in neonates, infants, and children after open heart surgery[J]. J Pediatr,2011,159(3): 414 -419.
  • 2Arzuaga A. Quantitation and stability of piperaeilin and tazobactam in plasma and uhrafiltrate from patient undergping continuous venovenous hemofiltration by HPLC biomed[J]. Chromatogr, 2012,19(8) :570 - 578.
  • 3Becker ML, Leeder JS. Identifying genomic and developmental causes of adversedrug reactions in children [J]. Pharmacogenomics, 2010,11(11): 1 591 - 1 602.
  • 4Vinks AA. Important role of population pharmacokinetic/phar- macodnamic modeling in pediatric therapeutics[J]. Journal of Pediatrics, 2011,159 (3) : 361 - 363.
  • 5Hayashi Y, Roberts JA, Paterson DL, et al. Pharmacokinetic eval- uation of piperacillin - tazobaetam[J]. Expert Opin. Drug Metab. Toxicol, 2010,6(8): 1 017 - 1 031.
  • 6Blonaiaux N. Daily serum piperacillin monitoring is advisable in critieally ill patients[J] . International Journal Of Antimierobial Agents, 2010,35: 500 - 503.
  • 7Valerie Au. High-performance liqid chromatographicof tazob- actam and piperacilin in human plasma and urine [J]. Journal of Chromatographic B, 1996 (682) : 125 - 136.
  • 8Arzuaga A. Quantitation and stability of piperacilin andtazobac- tam in plasma and uhrafihrate from patient un dergpingcontinuous venovenoush emofiltration by HPLC biomed[J]. Chromatogr, 2005,19 (8) : 570 - 578.
  • 9Shea KM,Cheatham SC,Wack MF,et al.Steady-state pharmacokinetics andpharmacodynamics of piperacillin/tazobactam administered by prolongedinfusion in hospitalised patients[J].Int J Antimicrob Agents,2009,34(5):429.
  • 10郑恒.哌拉西林/他唑巴坦钠的人体药动学[J].中国医院药学杂志,2009,29(18):1527-1530. 被引量:7

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部